(PRWEB) March 6, 2006
CNS disorders affect a vast patient population and represent a huge area of unmet therapeutic needs. In the United States alone, Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) afflict more than 6.5 million people. Drug discovery efforts for the most prevalent CNS diseases have met with varying success. It is estimated that billions of dollars are spent every year on prescription drug sales; however, many current therapies merely treat the symptoms but do not provide cures.
The complexity of CNS diseases makes this area a challenging but potentially very rewarding area for research. “Neurogenomics and Neurotherapeutic Strategies: New Directions in Platforms, Targets, and Therapeutic Approaches” evaluates drug development efforts in six major CNS diseases:
- Alzheimer’s Disease
- Parkinson’s Disease
- Amyotrophic Lateral Sclerosis
- Bipolar Disorder
This report surveys the numerous R&D efforts under way at companies and institutions around the world, focusing on discovery projects, preclinical studies, and early-stage human trials. It also addresses investigational methods, proposed mechanisms of action, pathways, and targets that research teams are exploring in order to move one step closer to developing effective therapeutics. Novel tools and platforms, including animal models, molecular imaging, and biomarkers, are also be covered.
“Neurogenomics and Neurotherapeutic Strategies: New Directions in Platforms, Targets, and Therapeutic Approaches” is available in hard copy and PDF format from Piribo. For more information, go to: http://www.piribo.com/publications/diseases_conditions/cns/cha010.html
Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,000 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.